Literature DB >> 1965032

Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cyclic AMP levels.

M Lee1, R T Jensen, S C Huang, G Bepler, L Korman, T W Moody.   

Abstract

Vasoactive intestinal polypeptide (VIP) receptors were characterized on non-small cell lung cancer (NSCLC) cells. 125I-VIP bound specifically to membranes derived from 6 NSCLC cell lines. Specific 125I-VIP was time dependent and a linear function of EPLC-65H membrane concentration. 125I-VIP bound with high (Kd = 0.2 nM) and moderate (Kd = 39 nM) affinity to two classes of sites. Pharmacology studies indicated that the order of peptide potency was VIP greater than rGHRH greater than PHI = helodermin greater than secretin greater than glucagon. Also VIP elevated the cAMP levels 10-fold using cell line ADLC-5M2. These data indicate that functional VIP receptors are present on NSCLC cells.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1965032     DOI： 10.1016/0196-9781(90)90153-v

Source DB:  PubMed          Journal:  Peptides        ISSN： 0196-9781            Impact factor:   3.750


  9 in total

1.  (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.

Authors:  Terry W Moody; Robert T Jensen; Mati Fridkin; Illana Gozes
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

2.  PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells.

Authors:  Terry W Moody; Alessia Di Florio; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2012-05-12       Impact factor: 3.444

3.  Characterization of the rat vasoactive intestinal polypeptide receptor gene 5' region.

Authors:  L Pei; S Melmed
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

4.  Pituitary adenylate cyclase-activating polypeptide causes increased tyrosine phosphorylation of focal adhesion kinase and paxillin.

Authors:  Terry W Moody; Julius Leyton; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2011-09-06       Impact factor: 3.444

5.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

Authors:  T W Moody; F Zia; M Draoui; D E Brenneman; M Fridkin; A Davidson; I Gozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

6.  PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells.

Authors:  Terry W Moody; Julius Leyton; Marchessini Casibang; Joseph Pisegna; Robert T Jensen
Journal:  Regul Pept       Date:  2002-11-15

7.  VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.

Authors:  Terry W Moody; James Dudek; Halina Zakowicz; James Walters; Robert T Jensen; Emmanual Petricoin; Chris Couldrey; Jeff E Green
Journal:  Life Sci       Date:  2004-01-30       Impact factor: 5.037

8.  PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells.

Authors:  Patrizia M Germano; Sandy N Lieu; Janjing Xue; Helen J Cooke; Fievos L Christofi; Yuxin Lu; Joseph R Pisegna
Journal:  J Mol Neurosci       Date:  2009-08-23       Impact factor: 3.444

9.  Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells.

Authors:  F Zia; M Fagarasan; K Bitar; D H Coy; J R Pisegna; S A Wank; T W Moody
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.